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Background: The triallelic serotonin transporter gene linked polymorphic region (5-HTTLPR) has been associated
with alterations in thermal pain perception. The primary aim of this study was to investigate the associations
between heat pain (HP) perception and the triallelic 5-HTTLPR in a large cohort of adults with chronic pain.
Methods: The cohort included 277 adults with chronic pain who met inclusion criteria, and were consecutively
admitted to an outpatient pain rehabilitation program from March 2009 through March 2010. Individuals were
genotyped for the triallelic 5-HTTLPR (including rs25531) and categorized as high, intermediate, or low expressors of
the serotonin transporter. Standardized measures of HP perception were obtained using a validated quantitative
sensory test method of levels.
Results: The distribution of the high, intermediate, and low expressing genotypes was 61 (22%), 149 (54%) and 67
(24%), respectively. The Hardy-Weinberg P-value was 0.204 which indicated no departure from equilibrium. A
significant effect of genotype was observed for values of HP threshold (P = 0.029). Individual group comparisons
showed that values of HP threshold were significantly greater in the intermediate compared to the high expressing
group (P = 0.009) but not the low expressing group (P > 0.1). In a multiple variable linear regression model, the
intermediate group (P = 0.034) and male sex (P = 0.021) were associated with significantly greater values of HP 0.5,
but no significant genotype-by-sex interaction effect was observed.
Conclusions: In this study that involved adults with chronic pain, the intermediate triallelic 5-HTTLPR expressing
group, but not the low expressing group, was associated with greater HP thresholds compared to the high
expressing group.Background
The effects of serotonin (5-HT) on pain are influenced by
the 5-HT transporter (5-HTT) which facilitates 5-HT
reuptake from the synaptic cleft [1]. The gene coding for
5-HTT (SLC6A4) has a 43 base-pair insertion/deletion in
the 5’- regulatory promoter region which is commonly
referred to as the 5-HTT linked polymorphic region
(5-HTTLPR) [2,3]. The 5-HTTLPR consists of a long (l)
and a short (s) allele. The s-allele variant has been associ-
ated with reduced transcription efficiency with resultant* Correspondence: hooten.william@mayo.edu
1Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester,
MN 55905, USA
2Department of Laboratory Medicine and Pathology, Mayo Clinic College of
Medicine, Rochester, MN 55902, USA
Full list of author information is available at the end of the article
© 2013 Hooten et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orreductions in 5-HTT expression and 5-HT reuptake. An
A to G substitution (rs25531) in the 5-HTT promoter has
also been described [4,5]. This single nucleotide poly-
morphism (SNP) has been found to influence 5-HTT gene
expression such that the minor G-allele, which is nearly
always in phase with the l-allele, reduces the efficiency of
5-HTT transcription to s-allele levels. These two polymor-
phisms, when studied jointly, have been referred to as the
triallelic 5-HTTLPR, and individuals can be categorized
as high (LA/LA), intermediate (SA/LA, LA/LG), or low ex-
pressors (SA/SA, LG/SA) of 5-HTT. Previous investigators
have suggested that 5-HTTLPR polymorphisms may ac-
count for a two-fold difference in mRNA levels [6,7].
The 5-HTT has important effects on thermal pain
perception in preclinical studies [8,9]. In human studies,
5-HTTLPR polymorphisms have been associated withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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not all, investigations that have predominately involved
healthy volunteers [10-14]. However, the associations be-
tween heat pain perception and the triallelic 5-HTTLPR
polymorphism have not been reported for a large cohort
of adults with chronic pain. This is of particular impor-
tance because individuals with chronic pain have alter-
ations in thermal perception [15-17], and the previously
reported associations between thermal pain perception
and the triallelic 5-HTTLPR polymorphism may be
varied among adults with chronic pain. Thus, the pri-
mary aim of this study was to investigate the asso-
ciations between heat pain (HP) perception and the




The study protocol was approved by the Mayo Foundation
Institutional Review Board, and written informed consent
was provided by all patients prior to study participation.
All adults consecutively admitted to the Mayo Com-
prehensive Pain Rehabilitation Center from March 2009
to March 2010 were eligible for study recruitment. During
this time period, 524 patients were admitted, and 300 met
inclusion criteria and were successfully recruited for study
participation. Inclusion criteria included admission to the
outpatient pain treatment program, chronic non-cancer
pain greater than 3 months duration, and age ≥ 18 years.
Exclusion criteria included the presence of a major me-
dical (e.g., severe cardiac or pulmonary disease), surgical
(e.g., spine or intraabdominal surgery within 6 months of
admission) or psychiatric disorder (e.g., schizophrenia, de-
mentia) that precluded full participation in the 3-week
outpatient treatment program.
The genotype of one subject could not be determined,
and baseline quantitative sensory test (QST) results were
not obtained on 22 subjects due to lack of available
study personnel. The distribution of high, intermediate
and low expressing genotypes among the 22 subjects
who did not have baseline sensory testing was 6 (27%), 9
(41%) and 7 (32%), respectively. Thus, the study cohort
was comprised of 277 subjects for whom both genotype
and QST data were available.
Study setting
The outpatient pain rehabilitation program was of 3-
weeks duration, and patients attended 8-hours daily. The
clinical setting has been previously described [18]. To
briefly summarize, a cognitive behavioral model served
as the basis for treatment, and the primary goal of the
outpatient program was restoration of physical and
emotional functioning. The majority of patients have
previously used multiple trials of analgesic medications,undergone surgeries, and utilized various interventional
pain procedures with incomplete pain relief. Examples of
common admitting diagnoses include low back pain,
fibromyalgia and chronic headache. Patients were involved
in daily physical and occupational therapy, and all patients
attended daily educational group sessions related to man-
agement of depressive symptoms, relaxation training,
stress management, activity moderation, and elimination
of pain behaviors.
Demographic and clinical characteristics
Baseline demographic and clinical characteristics were
collected at admission including age, sex, pain duration,
marital status, years of education, employment status,
primary pain site, and smoking status.
Determination of morphine equivalent dose
Upon admission, the daily opioid dose of each patient
was determined by self-report and review of pharmacy re-
cords, as previously described [19]. The daily opioid dose
was converted to daily morphine equivalents using an
equianalgesic conversion software program [20] that has
been used at our outpatient treatment center [19,21,22].
Measures
Pain severity
Pain severity was assessed using the pain severity
subscale of the Multidimensional Pain Inventory [23].
This self-report questionnaire has proven reliability and
construct validity [24]. The pain severity subscale is
quantified from the responses to the following three
questions: 1) “Rate the level of your pain at the present
moment”; 2) “On the average, how severe has your pain
been during the last week”; and 3) “How much suffering
do you experience because of your pain.” Raw scores
were converted to standardized t-scores with a norma-
tive value of 50 (range 0–100) and a SD of 10 [25].
Heat pain perception
Heat pain perception was assessed using the automated
Computer Aided Sensory Evaluator IV (CASE IV; WR
Electronics, Stillwater, MN) system based on the method
of levels [26-28], as previously described [16]. The CASE
IV system delivers discrete magnitudes of heat stimuli,
in units termed “just noticeable difference” (JND), inter-
spersed with null stimuli in random order through a
thermode with a surface area of 10 cm2. The baseline
temperature was 34°C, and the thermal rise rate was 4°C
per second. The levels of stimuli increased exponentially
and achieved a maximal peak at 48°C at level 21. For
levels 22, 23 and 24, the temperature of the thermode
was raised to 48°C for a duration of 1.5, 5 and 10 sec-
onds, respectively. At level 25, which was the maximal
heat stimulus, the temperature was raised to 49°C for a
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magnitude of the heat stimulus and whether or not a
null stimulus was delivered. After each stimulus, inclu-
ding all null stimuli, the subject was asked to grade the
intensity of the stimulus on an 11-point rating scale
where 0 denoted no pain and 10 signified the most pos-
sible intense pain. The test was completed when either
the subject rated the intensity of a heat stimulus ≥ 5 or
when the maximum stimulus had been delivered, which
avoids tissue injury. A quadratic regression equation was
then fitted to the pain ratings from which HP 0.5, HP 5
and HP 5–0.5 were calculated by the CASE IV software
program (WR TestWorks, version 2.0) [29,30]. Heat pain
0.5 was the midpoint between a nonpainful stimulus and
the least stimulus magnitude necessary to elicit a thresh-
old sensation of pain (Additional file 1: Figure S1). Heat
pain 5 was the stimulus magnitude necessary to elicit a
pain rating of 5 from the subject. It is important to note
that HP 5 was a measure of intermediately intense pain,
and not a measure of maximal heat pain tolerance. Heat
pain 5–0.5 was the difference between HP 5 and HP 0.5,
and has been termed the pain-stimulus response slope.
The standardized test procedures, stimulus waveform,
null stimulus, and the non-repeating stepping algorithm
between the different levels of heat stimuli have been
validated, and the HP test algorithm requires less than
5 minutes to complete [26-28,31].
Quantitative sensory testing was performed in a specif-
ically designated room. All patients using opioids were
on stable dosages at the time of testing. All study partici-
pants were tested using the dorsum of the nondominant
hand. This particular anatomical site was chosen because
of easy accessibility which was an important feasibility
consideration with regards to conducting QST in an am-
bulatory care setting.
Genotyping
DNA was extracted from whole blood at the Biospecimens
Accessioning Processing Laboratory at Mayo Clinic
Rochester using an automated platform (AutoGen
FlexStar Qiagen Chemistries), quantification was by UV
absorbance and quality was accessed by 260/280 OD
ratio. The simultaneous determination of the long and
short form of the 5-HTT promoter region and rs25531
was performed by PCR amplification of the promoter
region of 5-HTT using primers 5’-TCCTCCGCTTTGG
CGCCTCTTCC and 5’-TGGGGGTTGCAGGGGAGA
TCCTG, followed by Hpa II digestion of the resulting
amplicon as described by Wendlend et al. [5,32]. Sam-
ples were denatured for 1 cycle of 2 min at 94°C, annealed
for 30 cycles at 94°C for 30 sec, 58°C for 30 sec, 72°C for
1 min, and elongated for 10 min at 72°C. Digested
fragment sizes of 512 and 469 bp correspond to LA and
SA (long or short allele with “A” present at rs25531),respectively. The presence of G at rs25531 is indicative of
a digested fragment of 402 bp, and an additional fragment
of 69 or 100 bp for the short and long allele, respectively.
Statistical analyses
Demographics (age, sex, ethnicity, marital status, employ-
ment status, educational status) and clinical characteristics
(pain duration, smoking status, body mass index, primary
pain site, and daily morphine equivalent dose) were sum-
marized for the three 5-HTTLPR genotype groups. The
Hardy–Weinberg equilibrium (HWE) for genotypic distri-
bution was determined using the χ2 test for each group
[33]. Mean and standard deviation were reported for
continuous variables, and count and proportion were
reported for categorical variables. Group comparisons for
demographic and clinical characteristics were made using
unpaired t-tests for continuous variables and chi-square
tests for categorical variables. The normal distribution of
all QST measures was assessed using the Kolmogorov-
Smirnov test, and the median and interquartile range
(IQR) was reported. Nonparametric tests (Kruskal-Wallis
test) were used to assess for the main effect of the three
5-HTTLPR genotype groups on HP perception, and in-
dividual group comparisons were performed using the
Mann–Whitney U test.
Linear regression analyses were performed using HP
perception as the dependent variable. Univariate regres-
sions were performed separately on 5-HTTLPR genotype
and sex, where the 5-HTTLPR high expressing category
was the reference group and the intermediate and low
expressing categories were the comparison groups. To test
for interactions between genotype and sex, interaction
terms, which were calculated as the product of the geno-
type group and sex, were entered in a multiple variable
regression model as new variables. The final multiple vari-
able model contained both genotype and sex as independ-
ent variables. The residual plots of all regression analyses
were reviewed. The level of significance for all tests was
set at P < 0.05, and all analyses were completed using
PASW (IBM, Inc., Chicago, Il, Version 18.0).
Results
Sample characteristics
The study included 277 adults with chronic pain. The
distribution of the high, intermediate and low expressing
genotypes was 61 (22%), 149 (54%) and 67 (24%), respec-
tively. The Hardy-Weinberg P-value was 0.204 which
indicated no departure from equilibrium. Additional file
2: Table S1 contains a summary of demographic and
clinical characteristics. Fifty-two percent (n = 143) of the
cohort used daily opioids, and the mean morphine
equivalent dose was 46.1 ± 77.9 mg/day. No significant
differences were observed for opioid use, daily morphine
equivalent dose, or pain severity.
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Additional file 3: Figure S2 contains the distribution of
values for the parameters of HP perception. The values
of HP 5 (Kolmogorov-Smirnov Z = 0.90, P = 0.386) were
normally distributed, but HP 0.5 and HP 5–0.5 were not
normally distributed (P values for Kolmogorov-Smirnov
Z < 0.05).
Additional file 4: Table S2 contains the median and IQR
for values of HP 0.5, HP 5, and HP 5–0.5. A significant
effect of 5-HTTLPR genotype group on HP 0.5 was
observed (Kruskal Wallis = 7.074, P = 0.029). Individual
group comparisons showed that HP 0.5 was significantly
greater in the intermediate expressing group compared to
the high expressing group (Mann Whitney U = 3477.00,
Z = −2.67, P = 0.009), but no significant differences were
found between the intermediate and low expressing
groups (P > 0.10) (Additional file 5: Figure S3).
In univariable linear regression analysis with HP 0.5 as
the dependent variable, the intermediate expressing group
was associated with significantly greater values of HP 0.5
compared to the high expressing group, and male sex was
associated with significantly greater values of HP 0.5 com-
pared to females (Additional file 6: Table S3). In a multiple
variable linear regression analysis, an interaction effect
between genotype and sex was investigated; however, the
interaction terms were removed from the model due to
lack of significance (P values > 0.10). In the final multiple
variable regression model that included genotype and
sex as independent variables, the intermediate expressing
group was associated with significantly greater values of
HP 0.5 compared to the high expressing group, and male
sex was associated with significantly greater values of HP
0.5 compared to females (Additional file 6: Table S3).
Discussion
The main finding of this study was that individuals in
the intermediate expressing triallelic 5-HTTLPR poly-
morphism group had significantly greater HP thresholds
compared to individuals in the high expressing group.
This finding suggests that the intermediate expressing
group was less sensitive to threshold-level HP stimuli
compared to the high expressing group. No significant
difference in HP 0.5 was observed between the inter-
mediate and low expressing groups. In a multiple vari-
able linear regression model that included HP 0.5 as the
dependent variable and genotype and sex as independent
variables, the intermediate expressing group and male
sex were associated with significantly greater values of
HP 0.5. However, no significant genotype-by-sex inter-
action effect was observed, which suggested the inter-
mediate 5-HTTLPR genotype and sex had significant,
but independent, effects on HP 0.5. Additionally, no sig-
nificant differences in HP 5 or HP 5–0.5 were observed,
and the demographic and clinical characteristics of thecohort were similar among the three genotype groups
including sex, age, pain duration, primary pain diagnosis,
opioid use, daily morphine equivalent dose, and pain
severity.
Significantly greater HP thresholds among individuals
in the intermediate expressing group compared to the
high expressing group, but not the low expressing group,
has not been reported in previous studies. In an experi-
mental investigation that involved 44 healthy volunteers
of “European descent”, subjects in the high triallelic 5-
HTTLPR expressing group (n = 23) had significantly
lower HP thresholds (i.e., were more sensitive to heat
stimuli) compared to subjects in the low expressing
group (n = 21) [12]. However, subjects from the triallelic
5-HTTLPR intermediate expressing group were not
included in this particular study. In other studies
conducted by the same group of investigators, no
significant differences were found between the triallelic
5-HTTLPR genotype groups [10,11]. These findings
were partly consistent with the observations from an
experimental study that involved 58 patients with fibro-
myalgia and 60 healthy controls who were “Caucasian,
French-speaking” residents of Quebec province, Canada
[13]. In this particular study, the 5-HTTLPR poly-
morphism was not associated with differences in HP
thresholds, but subjects were not genotyped for the
rs25531 SNP which further influences the transcrip-
tional efficiency of 5-HTT [4,5]. In a final study that
involved 529 healthy subjects (72% Ashkenazi Jews of
Eastern European “origin”, 20% Sephardic Jews of North
African or Asian “origin”), the low expressing 5-HTTLPR
genotype was associated with decreased pain inhibition
compared to the high and intermediate groups [14]. Aside
from differences in genotyping, variations in HP percep-
tion among previous studies, including the findings of our
study, could be partly attributed to; 1) chronic pain asso-
ciated neuroplastic changes in 5-HT pathways, and 2) dif-
ferences in the methods used to assess thermal pain
perception.
The effects of 5-HT on pain perception are varied. In
the periphery, 5-HT has pro-nociceptive effects following
tissue injury [34], and exogenous administration of 5-HT
has been associated with hyperalgesia in preclinical and
clinical studies [35-37]. At the spinal level, 5-HT trans-
mission may either enhance descending inhibitory me-
chanisms or augment descending facilitatory pathways,
and the balance between inhibition and facilitation may be
partly influenced by neuroplastic changes that occur in re-
sponse to persistent pathological pain [38]. For instance,
decreases in 5-HT basal release have been observed in
preclinical studies using a neuropathic pain model [39,40],
but increases in 5-HT release have been reported in
chronic inflammatory models of pain [41,42]. Neuroplastic
changes in descending 5-HT pathways may also occur at
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receptor function have been observed in both central and
peripheral tissues [43,44], and upregulation of 5-HT1, 5-
HT2, 5-HT3 receptor subtypes have been reported in the
spinal cord [44-46]. Neuroplastic changes in 5-HT path-
ways have also been associated with alterations in 5-HTT
expression [47], which is consistent with previous studies
that document a role for 5-HTT in thermal nociception
[8,9]. Collectively, these studies suggest that neuroplastic
changes in 5-HT pathways, in response to persistent
pathological pain, could alter the effects of the 5-HTTLPR
polymorphism on HP perception. Therefore, neuroplastic
changes attributed to chronic pain could explain, in part,
why the findings of our study, which were derived from a
cohort of adults with chronic pain, differed from previous
studies that predominately involved healthy volunteers.
Differences in the methods used to assess thermal pain
perception could partly account for the disparate findings
of previous studies. In the method of limits, a thermal
stimulus is applied to the skin and increased, or decreased,
at a steady rate of 1°C/s. The HP threshold is the
temperature at which pain is experienced, and HP to-
lerance is the temperature at which the thermal stimuli
can no longer be tolerated. The test is typically repeated
three times, and the thermal pain threshold and tolerance
are calculated by averaging the temperatures from the re-
peated trials. The test procedures for the method of limits
have been validated [17,48], and have good reproducibility
over time [49]. However, several variations in the method
of limits were used in the previous studies. The Lindstedt
et al., [12] study most closely adhered to previously
published methodologies, and significant differences in
thermal pain thresholds were observed between the high
and low expressing groups. In this particular study, the
heat stimulus was changed at a rate of 1.5°C/s, and three
tests of HP and cold pain were performed. However, in a
separate study by Lindstedt et al. [11], subjects were
exposed to heat stimuli at temperatures of 46°C, 47°C, and
48°C for 15 seconds. Testing was repeated twice at each
temperature, and the application of each heat stimulus
was separated by a 30 second interval. In the Kosek et al.
[10] study, subjects were exposed twice to a temperature
of 48°C for 30 seconds, and a 10 minute interval separated
each temperature exposure. The rate of rise of the heat
stimuli was 0.3°C/s in the Potvin et al. study [13] where 3
tests were performed, and the rate of rise in the Treister
et al. study [14] was 10°C/s where 5 tests were performed.
The varying methods used to assess pain thresholds and
tolerances in these studies limits the ability to draw
more definitive conclusions about the effects of 5-
HTTLPR polymorphism on thermal pain perception
because exposure to different temperatures, or different
rates of temperature change, for varying durations of
time may have differential effects on the various 5-HTTLPR genotypes. However, despite these methodo-
logical variations, the effect size of the difference in ther-
mal pain threshold between the low and high expressing
5-HTTLPR groups ranged from 0.60 to 0.32 in 3 studies
that reported mean data. This range is comparable to the
effect size of 0.37 for the difference in HP threshold
between the intermediate and high expressing groups as
observed in our current study.
In this cohort of adults with chronic pain, no significant
group differences in demographic or clinical characte-
ristics were observed based on the triallelic 5-HTTLPR
genotype. This observation was similar to the findings of
previous studies where no consistent differences in demo-
graphic or clinical characteristics based on 5-HTTLPR
genotype have been observed in subgroups of adults with
chronic pain including fibromyalgia [50-52] and chronic
headache disorders [53-56]. However, various genotype-
by-sex interaction effects have been reported for the
5-HTTLPR polymorphism and thermal pain perception.
For example, a significant genotype-by-sex interaction
effect was reported by Lindstedt et al. [12] where low 5-
HTTLPR expressing females were less sensitive to cold
pain, but no significant genotype-by-sex interaction was
observed for HP perception. Alternatively, low express-
ing males had higher pain thresholds and tolerances in
response to electrocutaneous stimuli in a study that in-
volved 144 healthy volunteers of predominately “white
non-Hispanic” descent who were genotyped for the 5-
HTTLPR polymorphism but not the rs25531 SNP [57].
In our study, no significant genotype-by-sex interaction
effect was observed; rather the intermediate expressing
5-HTTLPR genotype and male sex were independently
associated with greater values of HP 0.5.
This study has limitations. The demographics and
clinical characteristics of the cohort could limit the
generalization of our observations. More specifically,
the majority of study participants were Caucasian
women residing in the United States, and only 5% were
from minority populations. However, in a study that
involved a random sample (N = 3,575) of community
dwelling adults with chronic pain derived from the
catchment area of our institution, 96% of individuals
were self-identified as “white” and 56% were female
[58]. Despite these demographic similarities, the clinical
characteristics of patients referred for multidisciplinary
pain rehabilitation at a tertiary referral medical center
could be different from the clinical characteristics of
a random sample of community dwelling adults with
chronic pain, as previously reported [15,16]. Thus, the
risk of referral bias can not be excluded, and the associ-
ations between HP perception and 5-HTTLPR polymor-
phisms may not be fully applicable in other populations
of adults with chronic pain. Although significant differ-
ences in thermal pain perception were found among the
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the lack of a control group could also limit the genera-
lization of our study findings.
Conclusions
In this study that involved a large sample of adults with
chronic pain, the three 5-HTTLPR genotypes had a sig-
nificant influence on thermal pain perception. Ongoing
research is warranted in order to further delineate the
effects of the triallelic 5-HTTLPR genotype on pain per-
ception in other large samples and subgroups of indivi-
duals with chronic pain.
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